retatrutide dosage in trials Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide Dosing Schedule: Week-by-Week Protocol

We have an obligation to understand the full biology of these drugs, not just the intended effect

Tirzepatide dosing follows a similar escalation pattern

The honest clinical picture is cautious: DSIP is investigational and research-only , much of the existing human data is older, limited, and inconsistent , and the available trials point in conflicting directions

Nearly 10,000 Michigan members lost coverage when Blue Cross Blue Shield of Michigan dropped the drugs for fully insured large groups

These are strategic decisions that either align with or work against the broader healthspan objectives of the combined approach

Diabetes GLP-1s perform better but still leak demand: Diabetes-indicated GLP-1s show higher retention (24% at one year) and face fewer access hurdles due to broader coverage and disease framing, yet 76% of demand remains unmet